Tenosynovial Giant Cell Tumor of Foot in a Patient with Radioiodine-Refractory Thyroid Cancer: Imaging Findings on FDG-PET/CT, MRI, and Radioiodine Scan
Abstract: We herein illustrate a case of benign tenosynovial giant cell tumor, which was incidentally detected as FDG-avid lesion on PET/CT in a patient with radioiodine refractory thyroid cancer, with predominantly non-iodine concentrating disease. The lesion was followed up clinically and with local MRI annually for subsequent 3 years. The utility of hybrid PET-CT imaging, the non-iodine concentration of the tumor along with clinical knowledge, and findings on other imaging and pathological modalities in answering and diagnosing incidental benign musculoskeletal tumors in a patient with known thyroid malignancy are presented here.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Tenosynovial Giant Cell Tumor of Foot in a Patient with Radioiodine-Refractory Thyroid Cancer: Imaging Findings on FDG-PET/CT, MRI, and Radioiodine Scan ; day:20 ; month:12 ; year:2022
World Journal of Nuclear Medicine ; (20.12.2022)
- Contributor
-
Loharkar, Sarvesh
Basu, Sandip
- DOI
-
10.1055/s-0042-1758804
- URN
-
urn:nbn:de:101:1-2023020211502212092699
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Loharkar, Sarvesh
- Basu, Sandip
Other Objects (12)
Progressive Unilateral Proptosis and (18F) FDG-Avid Lesions Connoting Aggressive Disease in Radioiodine-Refractory Differentiated Thyroid Carcinoma
Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status
NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer
Radioiodine Remnant Ablation: A Critical Review
Ultrasound-guided implantation of radioactive 125I seed in radioiodine refractory differentiated thyroid carcinoma
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features
Successful pregnancy without disease progression of radioiodine refractory papillary thyroid carcinoma: a case report
Clinico-pathological factors and [18F]FDG PET/CT metabolic parameters for prediction of progression-free survival in radioiodine refractory differentiated thyroid carcinoma
Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
Potential application of [18F]AlF-PSMA-11 PET/CT in radioiodine refractory thyroid carcinoma
Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma
Metabolomic screening of radioiodine refractory thyroid cancer patients and the underlying chemical mechanism of iodine resistance
Progressive Unilateral Proptosis and (18F) FDG-Avid Lesions Connoting Aggressive Disease in Radioiodine-Refractory Differentiated Thyroid Carcinoma
Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status
NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer
Radioiodine Remnant Ablation: A Critical Review
Ultrasound-guided implantation of radioactive 125I seed in radioiodine refractory differentiated thyroid carcinoma
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features
Successful pregnancy without disease progression of radioiodine refractory papillary thyroid carcinoma: a case report
Clinico-pathological factors and [18F]FDG PET/CT metabolic parameters for prediction of progression-free survival in radioiodine refractory differentiated thyroid carcinoma
Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
Potential application of [18F]AlF-PSMA-11 PET/CT in radioiodine refractory thyroid carcinoma
Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma
Metabolomic screening of radioiodine refractory thyroid cancer patients and the underlying chemical mechanism of iodine resistance
Progressive Unilateral Proptosis and (18F) FDG-Avid Lesions Connoting Aggressive Disease in Radioiodine-Refractory Differentiated Thyroid Carcinoma
Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status
NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer
Radioiodine Remnant Ablation: A Critical Review
Ultrasound-guided implantation of radioactive 125I seed in radioiodine refractory differentiated thyroid carcinoma
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features
Successful pregnancy without disease progression of radioiodine refractory papillary thyroid carcinoma: a case report
Clinico-pathological factors and [18F]FDG PET/CT metabolic parameters for prediction of progression-free survival in radioiodine refractory differentiated thyroid carcinoma
Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
Potential application of [18F]AlF-PSMA-11 PET/CT in radioiodine refractory thyroid carcinoma
Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma